CAR-T therapy for highly sensitized kidney transplant patients
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old with end-stage kidney disease and are waiting for a kidney transplant.
- You are a 'highly sensitized' patient, meaning your immune system has high levels of antibodies that make it hard to find a matching kidney.
- You either have a living donor with a positive crossmatch test, or you are on the waiting list with a PRA score of 80% or higher.
- You must be up to date on vaccinations and have tested negative for latent tuberculosis within the last 3 months.
- You are willing to stay in the hospital for at least 2 weeks after the study drug infusion and live within 2 hours of the hospital for an additional 2 weeks.
- You agree to use highly effective birth control (if applicable) for at least 3 years after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
This trial is testing a new type of cell therapy for advanced kidney cancer that has not responded to standard treatments. The therapy takes your own immune cells, modifies them to target a protein called CD70 on the cancer cells, and gives them back to you to help fight the cancer.
Hear when a new Highly Sensitized Patients Awaiting Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.